FDA approves sBLA for Takeda's Vonvendi for Von Willebrand disease
Vonvendi is the only recombinant Von Willebrand factor replacement therapy with approved indications in adults and children with VWD
Vonvendi is the only recombinant Von Willebrand factor replacement therapy with approved indications in adults and children with VWD
Agreement further expands Aptar Pharma’s leading position in nasal delivery solutions and addresses significant unmet needs of delivering drugs locally over extended periods
The company has received approval from DCGI to begin patient enrolment and dosing in the country
PendraCare Group develops, manufactures and sells innovative cardiology catheter solutions and provides design, development and manufacturing services to other global OEM’s
It will focus on interface between API and formulation manufacturing, reducing carbon footprint in formulation production, creating intellectual property, training next-generation scientists, and setting new industry benchmarks
Bain Capital and Cinven will each retain a minority stake, reflecting their ongoing confidence in STADA’s future growth
RTX001 represents a groundbreaking advance in the treatment of end-stage liver disease, offering new hope for patients with limited options
Now integrates with Abbott’s instinct sensor and approved for type 2 diabetes
He has successfully led the development of 15 approved drugs worldwide across various therapeutic areas over his more than 20-year career
Subscribe To Our Newsletter & Stay Updated